BioSpace News Archive

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr.

GT Medical Technologies, Inc. today announced that Per Langoe, a proven industry leader with in-depth radiation oncology experience has joined the company as CEO.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) today announced topline results from its clinical study comparing repeat doses of neffy (epinephrine nasal spray) to repeat doses of epinephrine intramuscular (IM) injection, as requested by the FDA with and without nasal allergen challenge (NAC) conditions.

Elephas Biosciences Corporation (Elephas), a biotechnology company, today announced that it will collaborate on the development of an oncology imaging diagnostics platform to predict response to immunotherapy with Mayo Clinic Comprehensive Cancer Center.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (PV).

Prolocor, Inc. today announced the acceptance of its abstract titled ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION at The American College of Cardiology (ACC) Scientific Sessions 2024 in Atlanta.

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are in the final stages of completing the clinical data report that will be submitted for approval by the Chinese National Medical Products Administration (NMPA).